

**BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B**

BioStock Life Science Spring Summit

Stockholm, June 8, 2022

Oskar Bosson, VP Communications and IR



Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- Investigational uses of an agent in development included in this presentation are not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BioArctic – a unique Swedish biopharma company

Improving life for patients with central nervous system disorders



High unmet need for disease-modifying treatments for Alzheimer's and Parkinson's diseases creates **large commercial opportunity**



World-class research and development driven organization with basis in founder's breakthrough discoveries and fruitful collaborations with leading **academic researchers** and **pharma companies** generating and developing **innovative projects**



Attractive and well-balanced project portfolio with projects from discovery through Phase 3 and combination of both proprietary projects with substantial marketing and out-licensing potential and partnered projects generating income



Well-financed with close to MSEK 800 (MUSD ~86¹) in cash and **valuable collaboration agreements**





Attractive and well-balanced project portfolio

	Project	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
ALZHEIMER'S DISEASE	Lecanemab (BAN2401) (<i>Clarity AD</i>)	Eisai ¹	Early Alzheimer's disease ³				
	Lecanemab (BAN2401) (<i>AHEAD 3-45</i>)	Eisai ¹	Preclinical (asymptomatic) Alzheimer's disease ⁴				
	BAN2401 back-up	Eisai					
	AD1801 (ApoE)						
	AD1503 (Trunc Abeta)						
	AD-BT2802						
	AD-BT2803						
	AD2603						
PARKINSON'S DISEASE	BAN0805 ² (alpha-synuclein)						
	PD1601 (alpha-synuclein)						
	PD1602 (alpha-synuclein)						
OTHER CNS DISORDERS	Lecanemab (BAN2401)		Down's syndrome ⁵ Traumatic brain injury ⁵				
	ND3014 (TDP-43/)		ALS				
	ND-BT3814 (TDP-43 with BT)		ALS				
BLOOD BRAIN BARRIER	Brain Transporter (BT) technology platform						

as of March 31, 2022

- 1) Partnered with Eisai for lecanemab (BAN2401) for treatment of Alzheimer's disease. Eisai entered partnership with Biogen regarding lecanemab (BAN2401) in 2014
- 2) AbbVie in-licensed BAN0805 in late 2018 and has developed the antibody with the designation ABBV-0805. On April 20, 2022, AbbVie informed BioArctic that it had taken a strategic business decision to terminate the collaboration regarding BioArctic's alpha-synuclein portfolio. We are currently working with AbbVie to transfer the projects back with the aim of finding a new committed partner
- 3) Mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease
- 4) Normal cognitive function with intermediate or elevated levels of amyloid in the brain
- 5) Dementia and cognitive impairment associated with Down's syndrome and with traumatic brain injury

Partnership model to de-risk clinical development and optimize commercialization opportunity


	Alzheimer's disease 	Parkinson's disease 
Partner track record	 <p>Discovered and developed world's best-selling medicine for symptoms in Alzheimer's</p> <p>Industry-leading pipeline in dementia area</p>	 <p>Used to treat confusion (dementia) related to Alzheimer's disease</p>
Collaboration and license	<p>Milestones of up to MEUR 151 remains to be received</p> <p>Royalties High single digit %</p> <p>BioArctic retains rights to lecanemab in other indications and option to market in the Nordics</p>	<p>Milestones of MUSD 130 received, out of MUSD 755</p> <p>Project transfer ongoing</p> <p>AbbVie has global rights to alpha-synuclein portfolio for all indications</p>

AbbVie has taken a strategic business decision to end its collaboration with BioArctic regarding its alpha-synuclein portfolio. BioArctic will now, in accordance with the license agreement, take back the project and prepare for future partnering.

Recent news – Alzheimer's disease


Alzheimer's disease – Lecanemab

- Eisai has **completed the rolling submission** to the FDA of lecanemab for early Alzheimer's disease under the accelerated approval pathway – awaiting FDA's acceptance of file and PDUFA date. BioArctic entitled to a milestone of MEUR 15 at acceptance
- Lecanemab was granted **Fast Track designation** by the FDA in December 2021 and **prior assessment review** by PMDA in March 2022
- Data presented at AD/PD congress in March continue to **further strengthen and differentiate lecanemab** towards competitors
- An article in Neurology and Therapy based on disease modeling suggests that **lecanemab could delay the progression** to Alzheimer's dementia by several years
- **Build-up of commercial organization** initiated



Disease modeling suggests that lecanemab could delay progression to Alzheimer's dementia by several years


Simulated mean time advancing to mild, moderate, and severe Alzheimer's disease (AD) dementia was longer for patients in the lecanemab-treated group than for patients in the standard of care group



The results from the modeling show the potential clinical value of lecanemab for patients with early AD and how it can slow the rate of disease progression, delay progression to AD dementia with several years and reduce the need for institutionalized care

1. Monfared et al. "Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling". *Neurol Ther.* 2022.
2. Swanson et al. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody". *Alzheimer's Res Ther.* 2021.
3. ADNI (Alzheimer's Disease Neuroimaging Initiative) study

Lecanemab – broad late-stage clinical program



Lecanemab – potential to lead the paradigm shift in the treatment of Alzheimer’s disease

Increased likelihood for lecanemab success

- Positive and consistent Phase 2b results
- Phase 2b OLE further strengthens the Phase 2b results
- Phase 3 study “Clarity AD” designed to confirm the positive Phase 2b results



Opportunity to be first with full approval in US, Japan and EU

- Accelerated approval pathway ongoing in the US and rolling submission completed May 2022
- Submission for full approval in the US, EU and Japan planned by Q1 2023, pending topline Phase 3 data expected fall 2022



Opportunity to differentiate

- Unique binding profile
- Rapid and profound brain amyloid clearance
- Early onset of clinical effect in slowing cognitive decline
- Good tolerability profile
- Full dose from day one



Further development programs

- Subcutaneous injection
- Blood biomarkers utilized to explore reduced dosing frequency for maintenance treatment
- Expanded Alzheimer’s disease populations:
 - Selected for AHEAD in pre-symptomatic individuals
 - Selected as background treatment for DIAN-TU NexGen study – dominantly inherited Alzheimer disease




Recent news – rest of portfolio

Parkinson's disease – BAN0805

- BioArctic has received a **new drug substance patent** in the US for BAN0805 against Parkinson's disease valid until 2041, with the possibility of a patent term extension up until 2046
- Encouraging pre-clinical data and Phase 1 results were presented at MDS congress in September 2021 and at the 4D meeting in May. The Phase 1 study **results support continued development** of the antibody into Phase 2 with dosing once a month
- On April 20, 2022, AbbVie informed BioArctic that they have made a strategic business decision to terminate the license agreement regarding BioArctic's alpha-synuclein portfolio. BioArctic will now, in accordance with the license agreement, **take back the project and prepare for future partnering**


Other

- **Expanding into ALS** as a new indication with a treatment targeting (TDP-43)
- **Expanding project portfolio** with BT technology combined with TDP-43 antibody



Upcoming news flow

Alzheimer's disease




Lecanemab (Eisai)

- Rolling submission for accelerated approval in the US completed in May 2022
- Clarity AD topline data expected fall 2022
- Data to be disclosed at international congresses

Discovery stage programs

- Advancement of projects

Parkinson's disease




BAN0805

- Data presented at international congresses

AbbVie has taken a strategic business decision to end its collaboration with BioArctic regarding its alpha-synuclein portfolio. BioArctic will now, in accordance with the license agreement, take back the project and prepare for future partnering.


Blood-brain barrier



Brain Transporter (BT) technology platform

- Further development of the technology platform
- Data to be disclosed at international congresses
- BT supporting the expansion of the project portfolio

Other CNS disorders




Neurodegeneration

- Data to be disclosed at international congresses

BioArctic: With Patients in Mind

Great science



Great projects



Great partners



Great people



GUNILLA OSSWALD, CEO



JAN MATTSSON, CFO



**OSKAR BOSSON, VP
COMMUNICATIONS & IR**



**NEXT REPORT & IR
CONTACT**

- **Next Report:**
Q2 Jan-Jun 2022
on July 12, 2022
- **Contact:**
Oskar Bosson,
VP Communications & IR
+46 704 10 71 80
ir@bioarctic.se

To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com